XML 258 R201.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other operating expenses - Other Income and Expense (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses € (4,382) € (3,443) [1] € (2,523) [1]
Other operating income 1,089 979 [1] 1,814 [1]
Other operating income/(expenses), net related to Regeneron (3,789) (2,979) (1,231)
Antibodies Collaboration agreement | Regeneron Pharmaceuticals, INC      
Disclosure Of Other Operating Income Expenses [Line Items]      
Commitments received for development costs 1,600 2,100  
Regeneron      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses (3,955) (3,206) (2,378)
Other operating income (expense) | Regeneron      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income 166 227 1,147
Monoclonal Antibody Alliance      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses (3,947) (3,196) (2,367)
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of monoclonal antibodies      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses (4,143) (3,321) (2,325)
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of Zaltrap      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income [2] 833 668 434
Monoclonal Antibody Alliance | Commercialization related expenses      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses (637) (543) (476)
Immuno-Oncology Alliance      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income 0 0 16
Others      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income and expenses € 158 € 217 € 1,120
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] (a)As of December 31, 2024, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development
costs amounted to €1.6 billion, compared with €2.1 billion as of December 31, 2023 (see Note D.21.).